Quantum Biopharma (QNTM) Cash from Financing Activities (2019 - 2026)

Quantum Biopharma (QNTM) has 6 years of Cash from Financing Activities data on file, last reported at $7.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 123.35% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (down 29.75% YoY), and the FY2025 full-year result was $6.1 million, down 47.51% from the prior year.
• Cash from Financing Activities improved to $7.0 million in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.0 million in Q1 2026 to a low of -$4.1 million in Q4 2022.
• A 4-year average of $1.7 million and a median of $1.4 million in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 450.97% in 2025, while the deepest fall reached 96.12% in 2025.
• Tracing QNTM's Cash from Financing Activities over 4 years: stood at -$4.1 million in 2022, then surged by 160.34% to $2.5 million in 2024, then sank by 42.68% to $1.4 million in 2025, then jumped by 394.82% to $7.0 million in 2026.
• Business Quant data shows QNTM's Cash from Financing Activities at $7.0 million in Q1 2026, $1.4 million in Q4 2025, and $261425.0 in Q3 2025.